

Peter W. Kenny  
Curriculum Vitae, 15-Dec-2009

### Personal details

Born: 09-04-1959, Port of Spain, Trinidad  
Citizenship: Dual national of UK and Trinidad and Tobago  
Email: [pwk.ntwrk.2007@gmail.com](mailto:pwk.ntwrk.2007@gmail.com)  
LinkedIn: <http://www.linkedin.com/pub/0/ab9/870>

### Profile

Physical-organic, computational and medicinal chemist. 20+ years of experience in molecular design, lead generation, lead optimisation and selection of compounds for screening. Specific research interests include fragment-based approaches to lead generation, hydrogen bonding, lipophilicity and automated editing of chemical structures.

### Employment history

1988-2009: AstraZeneca (formerly Zeneca; ICI Pharmaceuticals); Principal Scientist at retirement.  
1985-1987: University of Minnesota; Post-doctoral Research Associate  
1983-1985: University of the West Indies St Augustine; Assistant Lecturer and Demonstrator

### Education

1979-1982: Oxford University; D.Phil. in Physical-Organic Chemistry. Thesis Title: NMR Studies of Reaction Mechanisms  
1976-1979: Reading University; B.Sc. Chemistry with Subsidiary Mathematics, First Class Honours.

### Journal articles 2004-2009

Bethel, P.A.; Gerhardt, S.; Jones, E.V.; **Kenny, P.W.**; Karoutchi, G.I.; Andrew D. Morley, A.D.; Oldham, K. Rankine, N.; Augustin, M.; Krapp, S.; Simader, H.; Steinbacher S. **Design of selective Cathepsin inhibitors.** *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4622-4625.  
Asaad, N.; Bethel, P.A.; Coulson, M.D.; Dawson, J.E.; Ford, S.J.; Gerhardt, S.; Grist, M.; Hamlin, G.A.; James, M.J.; Jones, E.V.; Karoutchi, G.I.; **Kenny, P.W.**; Morley, A.D.; Oldham, K.; Rankine, N.; Ryan, D.; Wells, S.L.; Wood, L.; Augustin, M.; Krapp, S.; Simader, H.; Steinbacher, S. **Dipeptidyl nitrile inhibitors of Cathepsin L** *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4280-4283.  
**Kenny, P. W.** **Hydrogen bonding, electrostatic potential and molecular design.** *J. Chem. Inf. Model* **2009**, *49*, 1234-1244.  
Blomberg, N.; Cosgrove, D. A.; **Kenny, P.W.**; Kolmodin, K. **Design of compound libraries for fragment screening,** *J. Comput.-Aided Mol. Des.* **2009**, *23*, 513-525.  
Morley, A. D.; **Kenny, P. W.**; Burton, B.; Heald, R. A.; MacFaul, P. A.; Mullett, J.; Page, K.; Porres, S. S.; Ribeiro, L. R.; Smith, P.; Ward, S.; Wilkinson, T. J. **5-Aminopyrimidin-2-ynitriles as Cathepsin K inhibitors.** *Bioorg. Med. Chem. Lett.* **2009**, *19*, 1658-1661.  
Birch, A. M.; **Kenny, P. W.**; Simpson, I.; Whittamore, P. R. O. **Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors.** *Bioorg. Med. Chem. Lett.* **2009**, *19*, 850-853.

Colclough, N.; Hunter, A.; **Kenny, P. W.**; Kittlety, R. S.; Lobedan, L.; Tam, K. Y.; Timms, M. A. **High throughput solubility determination with application to selection of compounds for fragment screening.** *Bioorg. Med. Chem.* **2008**, *16*, 6611-6616.

Toulmin, A.; Wood, J. M.; **Kenny, P. W.** **Toward Prediction of Alkane/Water Partition Coefficients.** *J. Med. Chem.* **2008**, *51*, 3720-3730

Albert, J. S.; Blomberg, N.; Breeze, A. L.; Brown, A. J. H.; Burrows, J. N.; Edwards, P. D.; Folmer, R. H. A.; Geschwindner, S.; Griffen, E. J.; **Kenny, Peter W.**; Nowak, T.; Olsson, L.-L. Sanganee, H.; Shapiro, A. B. **An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.** *Curr. Top. Med. Chem.* **2007**, *7*, 1600-1629.

Birch, A. M.; **Kenny, P. W.**; Oikonomakos, N. G.; Otterbein, L.; Schofield, P.; Whittamore, P. R. O.; Whalley, D. P. **Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors,** *Bioorg. Med. Chem. Lett.* **2007**, *17*, 394-399

Leach, A. G.; Jones, H. D.; Cosgrove, D. A.; **Kenny, P. W.**; Ruston, L.; MacFaul, P.; Wood, J. M.; Colclough, N.; Law, B., **Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure,** *J. Med. Chem.* **2006**, *49*, 6672-6682.

Whittamore, P. R. O.; Addie, M. S.; Bennett, S. N. L.; Birch, A. M.; Butters, M.; Godfrey, L.; **Kenny, P. W.**; Morley, A. D.; Murray, P. M.; Oikonomakos, N. G.; Otterbein, L. R.; Pannifer, A. D.; Parker, J. S.; Readman, K.; Siedlecki, P. S.; Schofield, P.; Stocker, A.; Taylor, M. J.; Townsend, L. A.; Whalley, D. P.; Whitehouse, J., **Novel thienopyrrole glycogen phosphorylase inhibitors: Synthesis, in vitro SAR and crystallographic studies,** *Bioorganic & Medicinal Chemistry Letters* **2006**, *16*, 5567-5571.

**Kenny, P. W.**; Sadowski, J., **Structure modification in chemical databases,** *Methods and Principles in Medicinal Chemistry* **2005**, *23*(*Chemoinformatics in Drug Discovery*), 271-285.

Black, E.; Breed, J.; Breeze, A. L.; Embrey, K.; Garcia, R.; Gero, T. W.; Godfrey, L.; **Kenny, P. W.**; Morley, A. D.; Minshull, C. A.; Pannifer, A. D.; Read, J.; Rees, A.; Russell, D. J.; Toader, D.; Tucker, J., **Structure-based design of protein tyrosine phosphatase-1B inhibitors,** *Bioorganic & Medicinal Chemistry Letters* **2005**, *15*, 2503-2507.

Williams, E. J.; **Kenny, P. W.**; Kettle, J. G.; Mwashimba, P. G., **Synthesis of a 5-alkoxyprido[4,3-d]pyrimidin-4(3H)-one derivative via a regioselective Meisenheimer N-oxide rearrangement,** *Tetrahedron Letters* **2004**, *45*, 3737-3739.

Lyne, P. D.; **Kenny, P. W.**; Cosgrove, D. A.; Deng, C.; Zabłudoff, S.; Wendoloski, J. J.; Ashwell, S., **Identification of Compounds with Nanomolar Binding Affinity for Checkpoint Kinase-1 Using Knowledge-Based Virtual Screening,** *Journal of Medicinal Chemistry* **2004**, *47*, 1962-1968.

#### Patents 2004-2009

Piperazine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as antagonists of CC chemokines (CCR2b and CCR5) for the treatment of inflammatory diseases. Bower, J. F.; **Kenny, P. W.**; Poyser, J. P. PCT Int. Appl. **2007**, 110pp. WO 2007071952

Preparation of 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives as inhibitors of protein tyrosine phosphatase 1B. **Kenny, P. W.**; Morley, A. D.; Russell, D. J.; Toader, D. PCT Int. Appl. 2004, 48pp. WO 2004050646

Preparation of 5-(substituted phenyl)thiadiazolidin-3-ones as inhibitors of protein tyrosine phosphatase 1B. Birch, A. M.; **Kenny, P. W.**; Morley, A. D. Russell, D. J.; Toader, D. PCT Int. Appl. 2004, 89pp. WO 2004041799

#### **Non-Professional Interests**

Cricket, Skiing, Scuba-Diving, Travel.